- https://doi.org/10.1155/2024/6627035
Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center.
Translate Article 
Take Notes The pandemic situation of the novel coronavirus (severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and its associated disease (coronavirus disease 2019 (COVID-19)) represents a challenging condition with a plethora of aspects. The course of COVID-19 in patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) and rheumatic diseases (RD) is not well known. Our study is one step toward closing this gap by collecting data on vaccination rates, infection-free survival, and individual symptom severity. We conducted a prospective questionnaire-based study between April 2022 and October 2022 at our university hospital. Outward patients over the age of 18 years were screened for participation and reported about their infection/infection-free survival since the start of the pandemic. Finally, 156 patients were included in the study, 117 (75.0%) of which had inflammatory bowel disease and 39 (25.0%) patients with rheumatic disease. Altogether, 143 (91.7%) persons had received at least one vaccination against SARS-CoV-2. A total of 153 patients provided information regarding their COVID-19 history: 81 patients (52.0%) self-reported about their SARS-CoV-2 infection. In general, courses of infection were mild: only two patients (2.5% of patients with reported COVID-19) were hospitalized due to COVID-19 with one (1.2%) of the two needing intensive care. Asymptomatic COVID-19 had been described by 7 persons (8.6% of patients with reported COVID-19). Acute COVID-19 was accompanied by fatigue/tiredness in 58 persons (71.6% of patients with history of COVID-19) as the most frequent symptom. Other complaints were common cold (55 patients = 67.9%), cough (51 patients = 63.0%), headache (44 patients = 54.3%), and fever (35 patients = 43.2%). Stratified by vaccination status (unvaccinated vs. at least once vaccinated), the time to infection differed significantly (logrank test: p = 0.04, Chi2 4.1). At least once vaccinated people had a median COVID-19-free survival of 28.5 months (confidence interval (CI): 23.6 months-not reached). Without any vaccination, the estimated time to infection was 25.1 months (CI: 23.6 months-not reached). Our IMID patients have a high rate of vaccination against SARS-CoV-2. Data show a significantly longer infection-free survival in vaccinated IMID patients as compared to unvaccinated patients. Discrimination between symptoms of COVID-19 and a concomitant inflammatory disease is difficult as complaints might be overlapping. This trial is registered with DRKS00028880.
- # Severe Acute Respiratory Syndrome Coronavirus 2
- # Coronavirus Disease 2019
- # Inflammatory Disease
- # Immune-mediated Inflammatory Diseases
- # Immune-mediated Inflammatory Diseases Patients
- # Course Of Coronavirus Disease 2019
- # Severity Of Coronavirus Disease 2019 In Patients
- # Asymptomatic Coronavirus Disease 2019
- # Symptoms Of Coronavirus Disease 2019
- # Inflammatory Bowel Disease
- Peer Review Report
- 10.7554/elife.70458.sa1
- Aug 3, 2021
Decision letter: SARS-CoV-2 shedding dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19
- Research Article
135 - 10.1016/j.jhepr.2020.100169
- Aug 4, 2020
- JHEP Reports
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.
- Research Article
- 112
- 10.1053/j.gastro.2020.06.003
- Jun 6, 2020
- Gastroenterology
Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study
- Research Article
- 21
- 10.1053/j.gastro.2021.09.009
- Sep 8, 2021
- Gastroenterology
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
- Discussion
- 1
- 10.1053/j.jvca.2020.08.041
- Aug 26, 2020
- Journal of Cardiothoracic and Vascular Anesthesia
Testing the Asymptomatic Pre-Surgical Population for Severe Acute Respiratory Syndrome Coronavirus 2
- Research Article
- 62
- 10.1053/j.gastro.2020.05.009
- May 7, 2020
- Gastroenterology
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
- Peer Review Report
- 10.7554/elife.81182.sa1
- Sep 12, 2022
Decision letter: Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period
- Research Article
- 101
- 10.1053/j.gastro.2020.05.066
- May 29, 2020
- Gastroenterology
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease
- Discussion
- 2
- 10.1152/japplphysiol.00775.2020
- Oct 1, 2020
- Journal of Applied Physiology
Commentaries on Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies.
- Research Article
- 411
- 10.1016/j.jhepr.2020.100113
- Apr 2, 2020
- JHEP Reports
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.
- Discussion
- 10.1053/j.gastro.2021.01.014
- Jan 13, 2021
- Gastroenterology
Reply
- Front Matter
- 8
- 10.1053/j.gastro.2022.05.044
- Jun 2, 2022
- Gastroenterology
Rear Window—What Can the Gut Tell Us About Long-COVID?
- Research Article
- 2
- 10.1097/md.0000000000032705
- Jan 20, 2023
- Medicine
The rapid spread of coronavirus disease 2019 (COVID-19) has attracted worldwide attention. There were also reported gastrointestinal symptoms in patients with COVID-19. This work aims to analyze the global research trends in COVID-19 and digestive disease. The related papers on COVID-19 and digestive disease were identified with Pubmed and web of science core collection on September 3, 2021. Bibliometric visualization was conducted through VOSviewer and CiteSpace. The analytic research was based on original articles and reviews. There were 997 articles found, with citations ranging from 0 to 878. These articles were distributed among 86 countries and 355 journals. The USA mainly contributed (288 articles), where 3 of the top 10 institutions were located. Followed by China (215 articles) and Italy (160 articles). The highest level of scientific collaboration has been formed between the USA to China. The World Journal of Gastroenterology (39 papers) published the most significant number of articles. Concerning the research topic, the colon/small bowel had the largest number of articles, followed by the liver and pancreaticobiliary. "Liver injury," "inflammatory bowel disease," "management," and "endoscopy" were the hotspot keywords. The largest cluster of liver transplantation had offered hints regarding research frontiers. The analytic results showed that the liver, especially liver transplantation, and inflammatory bowel disease were the 2 most influential research topics in COVID-19 and digestive disease.
- Research Article
- 4
- 10.1016/j.mayocp.2020.09.021
- Sep 21, 2020
- Mayo Clinic Proceedings
Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors
- Research Article
- 151
- 10.1016/s2665-9913(20)30420-3
- Jan 7, 2021
- The Lancet. Rheumatology
COVID-19 vasculitis and novel vasculitis mimics.
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
